aortic root enlargement: why, when and how or it is time ...€¦ · transcatheter aortic valve...
TRANSCRIPT
![Page 1: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/1.jpg)
Aortic Root Enlargement: Why,
when and how
or
It is time to raise the bar and lower
the gradients!
MARK GROH MD
CHIEF, CV SURGERY
SURGICAL DIRECTOR, STRUCTURAL HEART
MISSION HOSPITAL, ASHEVILLE NC
![Page 2: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/2.jpg)
Conflicts:
Abbott – Structural Heart Advisory Board
![Page 3: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/3.jpg)
![Page 4: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/4.jpg)
Patient Prosthesis Mismatch
First Described by Rahimtoola in 1978
A condition in which the prosthetic aortic
valve is smaller than the native aortic valve
By this definition, all AVR inherently result in
mismatch
![Page 5: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/5.jpg)
![Page 6: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/6.jpg)
Patient Prosthesis Mismatch
Assessment at time of Surgery
Echocardiographic evaluation
Difficult due to shadowing from prosthesis,
LVOT, hemodynamics, anemia
Preoperative index by manufacturer valve
table and patient size to derive EOAI,
cm2/m2
![Page 7: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/7.jpg)
What
PPM????
![Page 8: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/8.jpg)
Manufacturer
released predictive
EOAI for specific
valve size in patients
with varied BSA
![Page 9: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/9.jpg)
PPM: Definitions
No PPM : EOAI > 0.85 cm2/m2
Moderate PPM: 0.65 cm2/m2 < EOAI <
0.85 cm2/m2
Severe PPM : EOAI < 0.65 cm2/m2
![Page 10: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/10.jpg)
Fig 1
The Annals of Thoracic Surgery 2018 105 14-22 Fallon et al
10 year review of
STS database 2004-
2014
59,779 patients
over the age of 65
undergoing
isolated SAVR cross
referenced with
Medicare
database
![Page 11: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/11.jpg)
The Annals of Thoracic Surgery 2018 105 14-22 Fallon et al
Survival
Significantly
Worse with PPM
Mod to none:
HR 1.08
95%CI 1.05-1.12
Severe to none
HR 1.32
95% CI 1.25-1.39
![Page 12: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/12.jpg)
European Heart Journal, Volume 33, Issue 12, June 2012, Pages 1518–1529,
https://doi.org/10.1093/eurheartj/ehs003\
All Cause mortality with PPM
Meta analysis of 99 studies with 27,186 patients and 133,141
patient years
Pooled estimate for all-cause mortality: ratios demonstrate the
significant additional hazard with prosthesis–patient mismatch
Moderate 1.19 HR 95% CI 1.07-1.33
Severe 1.84 HR 95% CI 1.38-2.45
![Page 13: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/13.jpg)
The Annals of Thoracic Surgery 2018 105 14-22 Fallon et al
CHF admissions are
higher in setting of
PPM
Moderate to No PPM
HR 1.15
95% CI 1.09-1.2
Severe to No PPM
HR1.37
95% CI 1.25-1.48
Moderate PPM
15% inc risk of admit
Severe PPM
37% inc risk of admit
![Page 14: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/14.jpg)
The Annals of Thoracic Surgery 2018 105 14-22 Fallon et al
Redo AVR
rates are
significantly
higher in
patients with
PPM
![Page 15: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/15.jpg)
SVD rates
Prosthesis-Patient Mismatch Predicts Structural Valve Degeneration in Bioprosthetic Heart Valves, Volume: 121, Issue: 19, Pages: 2123-
2129, DOI: (10.1161/CIRCULATIONAHA.109.901272)
Reoperation as an
indication of SVD
significantly higher
and earlier if PPM is
present
![Page 16: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/16.jpg)
Prosthesis-Patient Mismatch Predicts Structural Valve Degeneration in Bioprosthetic Heart Valves,
Volume: 121, Issue: 19, Pages: 2123-2129, DOI: (10.1161/CIRCULATIONAHA.109.901272)
![Page 17: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/17.jpg)
PPM leads more frequently to valve stenosis rather
than incompetence
Prosthesis-Patient Mismatch Predicts Structural Valve Degeneration in Bioprosthetic
Heart Valves, Volume: 121, Issue: 19, Pages: 2123-2129, DOI: (10.1161/CIRCULATIONAHA.109.901272)
Conclusions—These data suggest that stenosis-type SVD is an early,
PPM–related, and thus preventable phenomenon.
Incompetence-type SVD is a time-dependent, nonspecific wear
damage to bioprosthetic valves, which is not related to PPM.
![Page 18: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/18.jpg)
Effects of PPM
Adverse affect on valve durability
Increased incidence of readmission with
CHF, less LV mass regression
Higher mortality
![Page 19: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/19.jpg)
EOA Has a Complex Relationship With the Mean
Gradient Across the Aortic Valve and Prosthesis
There is no gradient until the
valve area is reduced by 50%.
Then, the gradient increases
gradually (red circles).
After the valve area is reduced
by 65%, the gradient increases
markedly (red line)
![Page 20: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/20.jpg)
The Annals of Thoracic Surgery 2018 105 14-22 Fallon et al
Moderate PPM
rates have
decreased 22%
and severe 55%
over the study
dates
In 2014 46.8% of
patients had
moderate PPM
and 6.2% severe
for isolated SAVR
![Page 21: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/21.jpg)
1) Hahn, RT, Pibarot, P, Stewart, WJ, Weissman, NJ, Gopalakrishnan, D, Keane, MG, ... & Herrmann, HC (2013). Comparison of transcatheter and surgical aortic valve replacement in severeaortic stenosis. JACC, 61(25), 2514-2521.
2) Reardon, MJ, Adams, DH, Kleiman, NS, Yakubov, SJ, Coselli, JS, Deeb, GM, ... & Heiser, J (2015). 2-year outcomes in patients undergoing surgical or self-expanding transcatheter aortic valve replacement. JACC, 66(2), 113-121.
3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence and sequelae of prosthesis-patient mismatch in transcatheter versus surgical valve replacement in high-risk patients with severe aortic stenosis: a PARTNER trial cohort-A analysis. J Am Coll Cardiol. 2014;64(13):1323-34.
4) Zorn GL III, Little SH, Tadros P, et al. Prosthesis-patient mismatch in high-risk patients with severe aortic stenosis: A randomized trial of a self-expanding prosthesis. J Thorac Cardiovasc Surg. 2016;151(4):1014-22,1023.e1-
![Page 22: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/22.jpg)
Early effect of
severe PPM
Prosthesis–patient mismatch in
high-risk patients with severe
aortic stenosis: A randomized
trial of a self-expanding prosthesis
Zorn et al JTCVS 2016: 151 issue
14 p 1014-1023
Patients with severe PPM at risk
of mortality and kidney injury
![Page 23: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/23.jpg)
Proprietary and confidential — do not distribute
PARTNER III – Low Risk Study 30 Day Results
1) Mack, Michael J., Martin B. Leon, Vinod H. Thourani, Raj Makkar, Susheel K. Kodali, Mark Russo, Samir R. Kapadia et al. "Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients." New England Journal of Medicine (2019).
![Page 24: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/24.jpg)
Proprietary and confidential — do not distribute
Published Meta-analysis in TAVR
Liao et al2017
Takagi et al2016
Overall PPM 33% 35%
Moderate PPM 25% 27%
Severe PPM 11% 8%
1) Liao, Yan-biao, Yi-jian Li, Li Jun-Li, Zhen-gang Zhao, Xin Wei, Jiay-yu Tsauo, Tian-yuan Xiong, Yuan-ning Xu, Yuan Feng, and Mao Chen. "Incidence, predictors and outcome of prosthesis-patient mismatch after transcatheter aortic valve replacement: A systematic review and meta-analysis." Scientific reports 7, no. 1 (2017): 15014.
2) Takagi, Hisato, Takuya Umemoto, and ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. "Prosthesis–patient mismatch after transcatheter aortic valve implantation." The Annals of thoracic surgery 101, no. 3 (2016): 872-880.
![Page 25: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/25.jpg)
Proprietary and confidential — do not distribute
62,125 TAVR patients
from 2014-2017
Severe PPM with
significantly increased
mortality risk and
readmission for HF at
1 year.
PPM in
TAVR
![Page 26: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/26.jpg)
Larger Valve size and EOAI result in hemodynamic
reserve
As the EOAI in smaller valves
decrease the relative change
within valve area occurs on the
steeper portion of the curve
and results in significant
increase in gradient, increasing
turbulence, jets and
inflammation leading to
progressive stenosis.
Small valves have less “EOAI
reserve”
![Page 27: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/27.jpg)
Aortic Root Enlargement
![Page 28: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/28.jpg)
![Page 29: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/29.jpg)
![Page 30: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/30.jpg)
![Page 31: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/31.jpg)
![Page 32: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/32.jpg)
![Page 33: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/33.jpg)
![Page 34: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/34.jpg)
![Page 35: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/35.jpg)
Results of “Hemodynamics First”
approach to SAVR
818 aortic valve replacements by single surgeon over 10 years
Exclusive use of Trifecta valve including the IDE trial
STS database and Social Security death registry
![Page 36: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/36.jpg)
TRIFECTA: Patients Demographics (n= 818)
Variable Mean or % ± SD or
(Frequency)
Age 71.03 ± 10.12
Gender, Male 67.12% (586)
BSA, M2 2.04 ± 2.04
CVD 21.15% (173)
CVA 6.60% (54)
Prior CABG 6.48% (53)
Prior valve 11.74% (96)
Prior MI 17.36% (142)
Hypertension 86.79% (710)
Chronic lung disease 18.19% (149)
Num. Dis. Vessels 2.10 ± 1.18
PAP, Sys, mmHg 37.70 ± 10.71
EF, % 52.09 ± 10.57
5
81
237
284
161
50
19 21 23 25 27 29
Valve size, mm
0
50
100
150
200
250
300
350
No
. o
f o
bservati
on
s
Valves Sizes and Distribution, Whole Series
5
81
237
284
161
50
19 21 23 25 27 29
Valve size, mm
0
50
100
150
200
250
300
350
No
. o
f o
bservati
on
s
![Page 37: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/37.jpg)
11%
28%
33%
21%
5%
1%
19 21 23 25 27 29
Valve Size, mm
Trifecta US Implantation
5
81
237
284
161
50
19 21 23 25 27 29
Valve size, mm
0
50
100
150
200
250
300
350
No
. o
f o
bservati
on
s
![Page 38: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/38.jpg)
TRIFECTA: PPM Assessment, n= 818
0.60 0.65 0.70 0.75 0.80 0.85 0.90 0.95 1.00 1.05 1.10 1.15 1.20 1.25 1.30 1.35 1.40 1.45 1.50
PPM
0
20
40
60
80
100
120
140
160
180
No.
of o
bser
vatio
ns
Expected Normal
114, 0r 13.9%
702, 0r 86.10%
2 o
r .0
24%
![Page 39: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/39.jpg)
PPM n %None, ≥
0.85 365 88.00%
Moderate,
≤0.85 and
>0.65 52 12.23%
Severe,
≤0.65 0
PPM n %None, ≥
0.85 335 84.29%
Moderate,
≤0.85 and
>0.65 63 15.71%
Severe,
≤0.65 2 0.005%
![Page 40: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/40.jpg)
2 26
04
12
4
14
2730
3532
2
37
29
0
52
81
6165
125
143
107
116
0
20
40
60
80
100
120
140
160
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Annular EnlargementTRF Implants
Trifecta Valve Implantation and Annular Enlargement Procedure (21%)
![Page 41: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/41.jpg)
Variable Enl,Yes Enl, No p SD, 1 SD, 2
Age 68.60 70.58 0.1205 10.77 10.66
Gender 1.54 1.34 0.0004 0.50 0.47
HeightCm 167.78 172.57 0.0005 9.47 11.83
Valve size 24.08 24.96 0.0005 1.96 2.14
EOAi Calc 0.98 1.00 0.1742 0.11 0.13
Chronic Lung Disease 1.60 1.34 0.0452 1.28 0.97
Cerebro-vascular Disease 1.73 1.86 0.0036 0.47 0.35
Perfusion Time, min. 82.45 76.52 0.1194 24.35 33.35
Aortic ClampTime, min. 60.23 51.57 0.0004 18.74 20.69
Mean prosthesis size 24.08 24.96 0.0005 1.96 2.14
Early Mortality 0.0112 0.0183 0.646766 0.1060 0.13421
Follow-up months 35.5539 47.2360 0.001674 25.9397 32.10207
Predicted Mortality 0.0292 0.0301 0.838497 0.0254 0.03117
Female, 53.93%
Male, 66.46%
p = 0.0004
![Page 42: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/42.jpg)
6
9
15
23
38
30
24
8
4
6
3
0
0.70 0.75 0.80 0.85 0.90 0.95 1.00 1.05 1.10 1.15 1.20 1.25
EOAi
0
5
10
15
20
25
30
35
40
45
No
. o
f o
bs
erv
ati
on
s
Expected Normal
No EnlargementMod/severe PPM – 37%
Histogram: New EOAi
4
11
16
31 31
35
16
13
43
2
0
0.60 0.65 0.70 0.75 0.80 0.85 0.90 0.95 1.00 1.05 1.10 1.15
New, calculated EOAi
0
5
10
15
20
25
30
35
40
No
. o
f o
bs
erv
ati
on
s
Expected Normal
After Enlargement
mod PPM 9%
![Page 43: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/43.jpg)
![Page 44: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/44.jpg)
Trifecta:Survival
Kaplan Meier Survival Function
0 20 40 60 80 100 120 140 160
Time, months
40%
50%
60%
70%
80%
90%
100%
Cu
mu
lati
ve P
rop
ort
ion
Su
rviv
ing
AVR, Isolated, n= 417
AVR, Complex, n= 401
Log-Rank test: p<0.0001
Survival @ 19 years
Isolated AVR: 69.39%
Complex AVR: 56.11%
![Page 45: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/45.jpg)
1
4 4
14
21
17
14
4
2
5
3
0
0.70 0.75 0.80 0.85 0.90 0.95 1.00 1.05 1.10 1.15 1.20 1.250
5
10
15
20
25
No
. o
f o
bs
erv
ati
on
s
Expected Normal Distribution
PPM. Severe = 0, Moderate = 9 (10.11%), None = 80 (89.9%)
2
5
15
32
27
5251
50
34
27
14
10
43
20
0.65 0.70 0.75 0.80 0.85 0.90 0.95 1.00 1.05 1.10 1.15 1.20 1.25 1.30 1.35 1.400
10
20
30
40
50
60
No
. o
f o
bs
erv
ati
on
s
Expected Normal Distribution
PPM. Severe = 0, Moderate = 32 (9.76%), None = 274 (83.5%)
![Page 46: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/46.jpg)
Concomitant procedures
Type n %
CABG 336 83.16%
Mitral VR* 79 19.55%
Tricuspid VR 28 6.93%
Pulmonary VR 8 1.98%
Variable Mean or % ± SD or
(Frequency)
Age 70.16 ± 10.70
Gender, Male 62.11% (259)
BSA, M2 2.02 ± 0.25
CVD 16.79% (70)
CVA 6.60% (54)
Prior CABG 4.08% (17)
Prior valve 13.91% (58)
Prior MI 9.95% (40)
Hypertension 86.79% (710)
Chronic lung dis. 18.19% (149)
EF, % 52.60 ± 10.40
Valve Sizes Distribution, AVR only (n= 417)
40
117
136
98
26
21 23 25 27 29
Valve Size, mm
0
20
40
60
80
100
120
140
160
No
. o
f o
bservatio
ns
![Page 47: Aortic Root Enlargement: Why, when and how or It is time ...€¦ · transcatheter aortic valve replacement. JACC, 66(2), 113-121. 3) Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence](https://reader035.vdocument.in/reader035/viewer/2022070808/5f0765547e708231d41cc65c/html5/thumbnails/47.jpg)